First Danish decision on the IPI measure in public procurement of medical devices
Background
The EU's International Procurement Instrument (IPI) allows the European Commission to adopt measures restricting access to EU public procurement procedures for tenderers, goods or services from third countries that do not provide comparable access to their own public procurement markets. In June 2025, the European Commission adopted an IPI measure targeting medical devices originating in China.
The IPI measure applies to public procurement procedures for specified medical devices, identified by relevant CPV codes, where the estimated contract value is at least EUR 5 million excluding VAT. In such procedures, contracting authorities must exclude tenderers originating in China from participation and ensure that products originating in China supplied by non-Chinese tenderers account for no more than 50% of the total contract value. Non-compliance may trigger a charge of between 10% and 30% of the total contract value.
For more information about the IPI measure and the obligations it imposes on contracting authorities and tenderers, see Plesner's previous Insight on the introduction of the IPI measure here.
The facts of the case
In November 2025, Region Midtjylland, Region Syddanmark and several municipalities initiated a procurement procedure for framework agreements for urology products. As the procurement procedure was subject to the IPI measure, the draft framework agreements included a requirement that goods originating in China could not exceed 50% of the total contract value, with non-compliance attracting a charge of between 10% and 30% of the total contract value.
During the procurement procedure, potential tenderers raised questions about the application of the IPI measure. The contracting authorities explained that the 50% requirement was a contractual obligation and that non-compliance would constitute a breach of contract. They also explained that a framework agreement could be awarded only to a tenderer that, based on its offer and supporting documentation, would be able to comply with the requirement during the contract term.
Vingmed A/S was initially awarded one of the framework agreements. However, following concerns raised by another tenderer, Unoquip GmbH, regarding the origin of Vingmed's products, the contracting authorities asked Vingmed to clarify how it would ensure compliance with the 50% requirement. Vingmed explained that the products were processed in China and argued that the exception available under the IPI should be applied. Subsequently, Vingmed confirmed that it would not be able to supply the products in accordance with the contractual requirement unless the exception applied.
Consequently, the contracting authorities withdrew the award to Vingmed, rejected its offer as non-compliant and instead awarded the framework agreement to Unoquip. Unoquip had stated in its offer that the products it proposed to supply were manufactured in China at the time of tendering, but that production would be moved outside China, or a new production facility would be established elsewhere during the contract term to enable compliance with the 50% requirement.
Following the new award decision, Vingmed submitted a declaration from its manufacturer stating that no more than 50% of the products to be supplied would originate in China, but the contracting authorities maintained their decision, leading Vingmed to lodge a complaint with the Complaints Board challenging both the rejection of its offer and the award of the framework agreement to Unoquip.
The Complaints Board's decision
The Complaints Board found that the contracting authorities had been entitled to reject Vingmed's offer as non-compliant. Vingmed's confirmation that it could not comply with the 50% requirement without an exception constituted a reservation in respect of that requirement. The fact that the framework agreement included a provision under which non-compliance would attract a charge did not alter that conclusion. The Complaints Board also placed emphasis on the fact that the contracting authorities had expressly stated during the procurement procedure that they could only award a contract to a tenderer able to meet the requirement during contract performance. The contracting authorities were therefore entitled to reject Vingmed's offer.
The Complaints Board also found that the subsequent manufacturer declaration, in the circumstances of the case, did not require the contracting authorities to withdraw the award to Unoquip and reconsider their rejection of Vingmed's offer. The declaration contradicted, rather than substantiated or clarified, Vingmed's earlier confirmation without explaining the discrepancy or how compliance with the requirement would be ensured. The contracting authorities were therefore not obliged to reopen their evaluation.
Vingmed's challenge to the award to Unoquip was also unsuccessful. The fact that Unoquip's products were manufactured in China at the time of tendering did not, in itself, prevent the award to Unoquip, as Unoquip had stated that it was actively working to move production outside China or establish a new production facility elsewhere and had confirmed this in response to the contracting authorities' enquiries. The Complaints Board therefore found that Unoquip had demonstrated that it would be able to comply with the 50% requirement during the contract term.
Plesner's comments
The decision is notable as it is the Complaints Board's first decision on the application of the IPI measure for medical devices since its adoption in June 2025. The significance of the issues raised is further underlined by the fact that the decision was made by an enlarged panel of the Complaints Board.
The IPI distinguishes between Chinese and non-Chinese tenderers. While tenderers originating in China are to be excluded from participation in procurement procedures, the same does not apply to non-Chinese tenderers supplying products originating in China. Instead, contracting authorities must require such tenderers to ensure, throughout the contract term, that products originating in China account for no more than 50% of the total contract value, and must impose a charge of between 10% and 30% of the total contract value in the event of non-compliance. Thus, the IPI does not provide for the exclusion of tenderers merely because they supply products originating in China.
The Complaints Board's decision nevertheless establishes that contracting authorities need not wait for a tenderer to breach the 50% requirement during contract performance before addressing an inability to comply with it. An express statement that the tenderer will be unable to comply with the requirement may constitute a reservation warranting rejection of its offer, just as a reservation in respect of any other contractual provision may do. This applies at least where the contracting authority has stated in the procurement documents that the ability to comply with the 50% requirement is a prerequisite for the award of the contract, notwithstanding the charge for non-compliance.
The decision also provides an indication of how contracting authorities may assess tenderers intending to change their supply chains after the tender deadline. It suggests that credible statements and plans to move production outside China or establish production capacity elsewhere may support a finding that a tenderer will be able to comply with the 50% requirement, in the absence of information indicating otherwise.
For contracting authorities, the decision underlines the value of stating clearly in the procurement documents that the tenderer's ability to comply with the 50% requirement during contract performance is a prerequisite for the award. This will enable contracting authorities to assess the tenderer's ability to comply before award of the contract.
For tenderers, the decision highlights the importance of mapping their supply chains and obtaining documentation from manufacturers before participating in tenders, enabling them to respond accurately to contracting authorities' enquiries about compliance with the IPI. Where products are manufactured in China at the time of tendering, tenderers should have credible plans for ensuring compliance with the 50% requirement and be able to explain those plans to the contracting authority.